share_log

EyePoint Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-10% Owner Adage Capital Management, L.P.

EyePoint Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-10% Owner Adage Capital Management, L.P.

EyePoint Pharmaceuticals | 3:首次持股聲明-股東 Adage Capital Management, L.P.
美股SEC公告 ·  04/23 04:18

牛牛AI助理已提取核心訊息

EyePoint Pharmaceuticals, Inc. (EYPT) has filed a Form 3 with the SEC, indicating a significant change in ownership by key insiders. The filing, dated April 18, 2024, reveals that Adage Capital Management, L.P. now beneficially owns 5,156,299 shares of EyePoint Pharmaceuticals' common stock indirectly, marking them as a 10% owner. The filing also lists Robert Atchinson and Phillip Gross, managing members of related entities to Adage Capital Management, as reporting persons. Both Atchinson and Gross have disclaimed beneficial ownership of the securities except to the extent of their pecuniary interest. The filing was completed and signed on April 22, 2024, by Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross.
EyePoint Pharmaceuticals, Inc. (EYPT) has filed a Form 3 with the SEC, indicating a significant change in ownership by key insiders. The filing, dated April 18, 2024, reveals that Adage Capital Management, L.P. now beneficially owns 5,156,299 shares of EyePoint Pharmaceuticals' common stock indirectly, marking them as a 10% owner. The filing also lists Robert Atchinson and Phillip Gross, managing members of related entities to Adage Capital Management, as reporting persons. Both Atchinson and Gross have disclaimed beneficial ownership of the securities except to the extent of their pecuniary interest. The filing was completed and signed on April 22, 2024, by Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross.
EyePoint製藥公司(EYPT)已向美國證券交易委員會提交了表格3,表明主要內部人士的所有權發生了重大變化。這份日期爲2024年4月18日的文件顯示,Adage Capital Management, L.P. 現在間接擁有5,156,299股EyePoint Pharmaceuticals普通股的實益股份,使其成爲10%的所有者。該文件還將Adage Capital Management關聯實體的管理成員羅伯特·阿欽森和菲利普·格羅斯列爲申報人。阿欽森和格羅斯都宣佈放棄對證券的實益所有權,但金錢利益除外。該文件由Adage Capital Management, L.P.、Robert Atchinson和Phillip Gross於2024年4月22日完成並簽署。
EyePoint製藥公司(EYPT)已向美國證券交易委員會提交了表格3,表明主要內部人士的所有權發生了重大變化。這份日期爲2024年4月18日的文件顯示,Adage Capital Management, L.P. 現在間接擁有5,156,299股EyePoint Pharmaceuticals普通股的實益股份,使其成爲10%的所有者。該文件還將Adage Capital Management關聯實體的管理成員羅伯特·阿欽森和菲利普·格羅斯列爲申報人。阿欽森和格羅斯都宣佈放棄對證券的實益所有權,但金錢利益除外。該文件由Adage Capital Management, L.P.、Robert Atchinson和Phillip Gross於2024年4月22日完成並簽署。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。